Novel nasal spray shows promise in preventing respiratory infections

New research published in Advanced Materials reports a novel nasal spray for preventing respiratory infections.

Myelofibrosis: Beyond Ruxolitinib

Up until fairly recently, ruxolitinib (Jakafi) was the only FDA-approved treatment for intermediate- and high-risk myelofibrosis, and thus has been the cornerstone of myelofibrosis treatment

Read More »